Evidence map›Paper›PMID 42637557›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2026

Tracking the Continuous Time Dynamics of Tau and Depressive Symptoms across the Alzheimer's Disease Continuum.

Teodora Z Markova, Margo B Heston, Anne S Berry, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Teodora Z MarkovaVolen Center for Complex Systems, Brandeis University, Waltham, Massachusetts 02453 teodoramarkova@brandeis.edu.
Margo B HestonEdward and Pearl Fein Memory and Aging Center, Department of Neurology, University of California, San Francisco, California 94158.
Anne S BerryVolen Center for Complex Systems, Brandeis University, Waltham, Massachusetts 02453.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Upregulated Norepinephrine Synthesis Capacity in AgingR01AG074330 · NIA · BRANDEIS UNIVERSITY · PI Anne Shively Berry · 2022 to 2026
$6.2M
Dopaminergic mechanisms of resilience to Alzheimer's disease neuropathologyR21AG081759 · NIA · BRANDEIS UNIVERSITY · PI BERRY, ANNE SHIVELY · 2023 to 2023
$437k
The Disadvantage Exposome as a Driver of Alzheimer’s Disease PathologyK00AG097172 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Margo Heston · 2025 to 2026
$169k
Associations among monoamines, tau pathology and emotional memory in agingF31AG087628 · NIA · BRANDEIS UNIVERSITY · PI Teodora Markova · 2025 to 2026
$72k
NIA NIH HHS F31 AG087628NIA NIH HHS K00 AG097172NIA NIH HHS R01 AG074330NIA NIH HHS R21 AG081759NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

In aging and Alzheimer's disease (AD), higher levels of tau pathology often coincide with an increased number of depressive symptoms. To establish probable causality between tau accumulation and depressive symptom trajectories, we applied three complementary analysis approaches using longitudinal positron emission tomography ([18F]flortaucipir) and Geriatric Depression Scale (GDS) data in male and female humans from the Alzheimer's Disease Neuroimaging Initiative. Participants were not clinically depressed at baseline and were categorized as cognitively normal (CN) or cognitively impaired (mild cognitive impairment (MCI)/AD dementia). Linear mixed effects models revealed rates of tau accumulation significantly moderated how quickly depressive symptoms increased over time in the CN sample, while GDS slopes did not moderate tau accumulation. We used continuous time structural equation modeling to test directionality and found that, in the CN sample, greater tau predicted higher subsequent GDS, while variability in GDS did not predict later tau. Finally, we tested the hypothesis that, if tau drives increasing depressive symptoms, the onset of tau positivity would be accompanied by worsening depressive trajectories. In the CN sample, longer duration of tau positivity was associated with steeper increases in GDS scores. No significant results were observed in the MCI/AD dementia sample, suggesting the unique value of early temporal windows for disentangling how affective and neuropathological changes contribute to disease progression. Together, these findings support a model by which early tau deposition in cognitively unimpaired older adults likely contributes to the emergence of depressive symptoms, while depressive symptoms exert little influence on tau at this stage.

Indexed as

Alzheimer DiseaseDepressiontau ProteinsAgedAged, 80 and overCognitive DysfunctionDisease ProgressionFemaleHumansLongitudinal StudiesMalePositron-Emission Tomographytau ProteinsAlzheimer’s diseasedepressive symptomsneuroimagingtautime dynamics

Identifiers

PMID42637557
PMCPMC13560904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.